Sjögren syndrome (SS) comprises glandular and extraglandular manifestations. Double-blind prospective trials of traditional disease-modifying antirheumatic drugs and biologics have failed because they have not improved benign symptoms, the major cause of lowered quality of life. Rituximab has proven effective in SS patients with associated mixed cryoglobulinemia, parotid gland swelling, lymphocytic interstitial pneumonitis, thrombocytopenia, and other manifestations. There were few of these SS patients in the trials required for FDA approval. Most patients had benign symptoms and did not show benefit, leading to failure of the study. This article examines the reasons for these failures and proposes future directions.
Keywords: Benign glandular manifestations; Danger hypothesis; Danger-associated molecular patterns; Extraglandular manifestations; Functional circuit; Keratoconjunctivitis sicca; Neurohypothalamic-immune axis; Sjögren syndrome.
Copyright © 2016 Elsevier Inc. All rights reserved.